14 Best 52-Week High Stocks To Buy According to Analysts

Page 5 of 13

9. Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

52 Week Range: $3.03 – $15.00

Current Share Price: $13.42

Stock Upside Potential: 31.77%

Number of Hedge Fund Holders: 8

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a specialty pharmaceutical company that develops, acquires, and commercializes pharmaceutical products for rare diseases. It offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency. The stock exploded in 2024, rallying by 228%. The rally to 52-week highs came as the market reacted to an aggressive acquisition drive as the company continued to strengthen its product portfolio.

In addition, the stock has been trading higher owing to stellar financial results. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) delivered a 15th consecutive quarter of revenue growth, with product sales increasing by 40% in the third quarter to $9.8 million. Eton has also moved to strengthen its revenue base with plans to acquire 10 commercial products with the prospects of generating $100 million in revenue in the rare disease portfolio.

As part of its acquisition drive, Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has agreed to acquire US rights to Amglidia, a treatment developed for neonatal diabetes mellitus. The acquisition aligns with the company’s bid to strengthen paediatric endocrinology. In addition, it has completed the asset purchase of Increlex®, a biologic product used to treat pediatric patients 2 years of age and older struggling with insulin-like growth factor 1 deficiency (SPIGFD). ETON also plans to start commercializing Galzin, an FDA-approved maintenance treatment for patients with Wilson’s disease who have been initially treated with a chelating agent, as it looks to strengthen its revenue streams.

Page 5 of 13